HeyJaredNeetu Chandra Sharma
- Indexed articles, last 90 days
- 37
- Latest publication
- Sep 29, 2026
- Outlet visibility, for Business Today
- Top 50K sites
- Earliest in this view
- Jul 9, 2026
Latest articles
How new safety evidence is boosting India’s expanding Ashwagandha market - BusinessToday (opens the original)
Read excerpt
As the use of Ashwagandha expands in India and global markets, a large clinical trial backed by the Ministry of Ayush has found that a standardised Ashwagandha root extract was well tolerated when taken daily for 24 weeks, with no treatment-related liver or kidney injury reported. Ashwagandha, traditionally used in Ayurveda, has become a widely marketed ingredient in herbal and health products in India and overseas.
IRDAI’s insurance distribution reforms: What changes for insurers, brokers, customers - BusinessToday (opens the original)
Read excerpt
IRDAI is looking to put a tighter lid on the cost of distributing insurance, while changing the way commissions are decided. The proposals could affect insurers and intermediaries differently, depending on the product, distribution channel and cost of servicing customers. For some low-ticket products, lower commissions could make traditional distribution less attractive and push more sales towards digital channels.
FSSAI proposes curbs on sale of non milk products as ‘paneer’ - BusinessToday (opens the original)
Read excerpt
The Food Safety and Standards Authority of India (FSSAI) has proposed restricting the manufacture and sale of analogue products as ‘paneer’, saying products made from constituents not derived from milk should not be represented as paneer. The food regulator has proposed an amendment to the Food Safety and Standards (Prohibition and Restrictions on Sales) Regulations, 2011, to specifically cover “paneer made of constituents not derived from milk.” The draft has been issued with the previous appro
GLP 1 drugs are under fresh scrutiny over rare condition; here's what's happening - BusinessToday (opens the original)
Read excerpt
Danish drugmaker Novo, formerly Novo Nordisk, on Friday cited data from its own clinical trials that recorded cases of a rare eye condition causing vision loss among people taking its GLP-1 medicines. The statement comes as studies based on real-world patient records have reported an association between semaglutide and the eye condition, European regulators have classified NAION as a very rare side effect of semaglutide, and US litigation involving Novo and US drugmaker Eli Lilly is under way.
What triggered PB Fintech’s 20% fall even as it bets big on health, pension expansion - BusinessToday (opens the original)
Read excerpt
PB Fintech shares hit the 20% lower circuit on Thursday after the insurance regulator proposed changes to distributor commissions that could lower payouts across several products. The Insurance Regulatory and Development Authority of India (IRDAI) has proposed linking commission caps to product type, distribution channel, complexity and servicing effort, with lower limits for several categories. PB Fintech fell to ₹1,508.90 from Wednesday’s close of ₹1,886.30. The regulator has invited comments
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Business Today, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.